Where Eteplirsen Is Sold and Distributed
Eteplirsen (brand name Exondys 51), developed by Sarepta Therapeutics, is distributed exclusively in the United States. The FDA approved it in 2016 for treating Duchenne muscular dystrophy (DMD) in patients with confirmed exon 51 skipping mutations amenable to exon 51 skipping.[1] Sarepta handles manufacturing and distribution through specialty pharmacies and infusion centers within the U.S. healthcare system. It is not approved or commercially available in Europe, Canada, Australia, or other major markets, where regulatory filings have faced rejections or delays.[2]
Why Limited to the U.S.?
The European Medicines Agency (EMA) rejected eteplirsen in 2021 due to insufficient evidence of clinical benefit, blocking EU distribution.[3] Similar hurdles exist elsewhere: Health Canada denied approval in 2017, and Japan's PMDA has not granted marketing authorization despite ongoing trials. Sarepta's focus remains U.S.-centric, with over 99% of global sales from American patients.[4]
How U.S. Patients Access It
Patients receive eteplirsen via intravenous infusion, typically 30 mg/kg weekly, covered under Sarepta's Expanded Access Program or insurance. Distribution occurs through SareptAssist, which coordinates with certified pharmacies like Accredo or CVS Specialty for home delivery or clinic administration. Only ~13% of DMD patients qualify due to the specific mutation.[5]
Global Trials and Future Expansion
Ongoing Phase 3 trials (e.g., Study 4053-101) test eteplirsen in Japan and other regions, but no non-U.S. approvals are imminent. Sarepta prioritizes U.S. market growth over international launches amid patent protections lasting until 2030+.[6]
Alternatives Outside the U.S.
Non-U.S. patients often use off-label exon-skipping therapies like Wave Life Sciences' suvodirsen (failed Phase 3) or gene therapies like Pfizer's fordadistrogene movaparvovec (under review in Europe). Steroids like deflazacort remain standard care globally.[7]
[1]: FDA Approval Summary for Exondys 51
[2]: Sarepta Therapeutics SEC Filings
[3]: EMA Rejection Assessment Report
[4]: Sarepta Q4 2023 Earnings
[5]: Sarepta Patient Services
[6]: DrugPatentWatch.com - Eteplirsen Patents
[7]: Parent Project Muscular Dystrophy Pipeline Report